FIELD: biotechnology.
SUBSTANCE: invention relates to a tetraspecific antibody monomer that binds to CD19, CD3, 4-1BB and PD-L1, as well as to an antibody containing it. Also an isolated nucleic acid encoding the above antibody is disclosed, as well as a vector and a cell containing it are disclosed. The invention also relates to a method of producing a tetraspecific antibody, including culturing the above host cell, as well as a composition containing the above antibody.
EFFECT: invention is effective for the treatment of cancer associated with CD19, CD3, 4-1BB and PD-L1.
21 cl, 8 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| 5T4 AND 4-1BB ANTIGEN-BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | 2018 |
|
RU2804458C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| MODIFIED HEMATOPOIETIC STEM CELLS/PROGENITOR CELLS AND NON-T EFFECTOR CELLS, AND USE THEREOF | 2014 |
|
RU2733652C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-NK-CELLS | 2020 |
|
RU2795443C2 |
| TRISPECIFIC BINDING MOLECULES FOR TREATING VIRAL HEPATITIS B INFECTION AND BOUND STATES | 2016 |
|
RU2733496C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
